Table 3

 Demographic and clinical characteristics of the patients included

COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; FiO2, fraction of inspired oxygen; GP, general practitioner.
Numbers included
    Number included in the quality improvement project (Appendix A available online at http://thorax.bmj.com/supplemental gives data on full cohort)503
    Number of patients with full data for all four tools419
Demographics
    Sex47% male (n = 197)
    AgeMedian (range)  = 74 (16–98) years
Age >65 years = 70% (n = 292)
    Living in own home84% (n = 351)
    Living alone36% (n = 152)
Clinical characteristics
    Antibiotic from GP before admission42% (n = 149/356)
    CRP >5076.5% (n = 286/374)
    Chest radiograph consistentwith pneumonia95% (218/230)
Severity assessment on admission
CURB65 score
    0 or 133.5% (n = 140)
    228.5% (n = 119)
    ⩾338% (n = 160)
    Respiratory rate ⩾30/min22% (n = 91)
    Systolic blood pressure <90 mm Hg6% (n = 24)
    Diastolic blood pressure ⩽60 mm Hg25% (n = 103)
    Pulse ⩾125/min10% (n = 43)
    Pulse oximetry <92% (any FiO2)33% (n = 140)
    Blood urea >7 mmol/l58% (n = 242)
New confusion31% (n = 129)
    % without comorbidity35% (n = 147)
    % with asthma/COPD35% (n = 146)
Initial antibiotic regimen
    Broad spectrum betalactam + macrolide48% (n = 201)
    Narrow spectrum betalactam + macrolide31% (n = 130)
    Betalactam monotherapy10% (n = 42)
    Macrolide monotherapy3% (n = 13)
    Levofloxacin2% (n = 8)
    Others6% (n = 25)
Outcomes
    % of patients transferred to theintensive care unit3% (n = 13)
    30-day post admission mortality19% (n = 79)
    Length of hospital stay (excludes deaths)Median (range)  = 5 (0–116) days